Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Guardant Health Inc (GH)

Guardant Health Inc (GH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Guardant Health Inc 3000 Hanover Street Palo Alto CA 94304 USA

P: 855-698-8887 F: 888-974-4258

Description:

Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.

Key Statistics

Overview:

Market Capitalization, $K 5,604,723
Enterprise Value, $K 5,806,793
Shares Outstanding, K 102,220
Annual Sales, $ 373,650 K
Annual Net Income, $ -405,670 K
Last Quarter Sales, $ 109,140 K
Last Quarter Net Income, $ -229,430 K
60-Month Beta 0.70
% of Insider Shareholders 5.90%
% of Institutional Shareholders 89.36%
Float, K 96,189
% Float 94.10%
Short Volume Ratio 0.41

Growth:

1-Year Return -43.74%
3-Year Return -10.93%
5-Year Return 0.00%
5-Year Revenue Growth 1,379.80%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.25 on 08/04/22
Next Earnings Date 11/03/22
Earnings Per Share ttm -5.41
EPS Growth vs. Prev Qtr -85.95%
EPS Growth vs. Prev Year -134.38%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payable Date 03/13/15
Dividend Payout Ratio 0.00%

GH Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -99.90%
Return-on-Assets % -26.20%
Profit Margin % -108.57
Net Margin % N/A
Debt/Equity 3.56
Price/Sales 14.73
Price/Cash Flow N/A
Price/Book 17.25
Book Value/Share 3.12
Interest Coverage -148.02
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar